Xenon Pharmaceuticals XENE · NASDAQ
$35.34 -3.18% (-$1.16)
Summary
45 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $119.5M against $6.42M.
- The price moves less than the market (beta 0.60).
What to watch
- Revenue fell by 7.4% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
- Analysts expect revenue to fall by 82% this fiscal year.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Is it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 25% a year over 5 years. Over the last 3 years it fell by 7.4% a year. For the next fiscal year analysts expect revenue to fall by 82%.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $409.2M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 21
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $68.63 is 94% above today's price. 95% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2022By product
- License and Service 100%
By region
The company reports no revenue by region.
License and Service brings in 100% of revenue.
Segments in detail